Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 4, 2010, Pages 253-263

  Wang, Weirong ^a   Prueksaritanont, Thomayant ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allometry; Human clearance prediction; Interspecies scaling; Pharmacokinetics; Therapeutic proteins

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON A; ALTEPLASE; ANTINUCLEAR ANTIBODY; BEVACIZUMAB; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CD4 ANTIBODY; DACLIZUMAB; DIGOXIN; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; HIRUDIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; LENERCEPT; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY FAB 2; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMITEPLASE; RECOMBINANT ERYTHROPOIETIN; SARUPLASE; TENECTEPLASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; MONOCLONAL ANTIBODY; PROTEIN;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; HUMAN; MONKEY; NONHUMAN; RABBIT; RAT; SPECIES COMPARISON; ANIMAL; BIOLOGICAL MODEL; HAPLORHINI; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; HAPLORHINI; HUMANS; MODELS, BIOLOGICAL; PROTEINS; SPECIES SPECIFICITY;

EID: 77955297665     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.708     Document Type: Article

References (50)

1. Baumann A. Early development of therapeutic biologics-pharmacokinetics. Curr Drug Metab 2006; 7: 15-21.
2. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
3. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.
4. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35: 86-94.
5. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8: 1351-1359.
6. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 2004; 93: 177-185.
7. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227.
8. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 1028-1040.
9. Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 2009; 98: 3850-3861.
10. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
11. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol 1998; 150: 295-300.
12. Ho M, Silamut K, White NJ et al. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 1990; 42: 260-266.
13. Braeckman R. Pharmacokinetics and pharmaco-dynamics of protein therapeutics. In Peptide and Protein Drug Analysis, Reid RE (ed.). Marcel Dekker Inc: New York, 2000; 633-669.
14. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and inter-species scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 75-78.
15. Stokol T, Trepanier L, Parry BW, Finnin BC. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 1997; 63: 23-27.
16. Grene-Lerouge NAM, Bazin-Redurea MI, Debray M, Scherrmann JMG. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 1996; 138: 84-89.
17. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; 28: 483-493.
18. Srinivas NR, Weiner RS, Shyu WC et al. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J Pharm Sci 1996; 85: 296-298.
19. Srinivas NR, Shyu WC, Weiner RS et al. Assessment of dose proportionality, absolute bioavail-ability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosup-pressive agent, following subcutaneous and intravenous administration to rats. Pharm Res 1997; 14: 911-916.
20. Srinivas NR, Weiner RS, Warner G et al. Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosup-pressive agent, in monkeys following multiple doses. J Pharm Sci 1996; 85: 1-4.
21. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 1995; 84: 1285-1290.
22. Keith JC, Ferranti TJ, Misra B et al. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 1994; 73: 101-105.
23. McCarthy K, Stewart P, Sigman J et al. Pharma-cokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002; 87: 824-830.
24. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35(suppl 2): 33-38.
25. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 2007; 35: 1672-1678.
26. Flaharty KK, Caro J, Erslev A et al. Pharmaco-kinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47: 557-564.
27. Davis CB, Hepburn TW, Urbanski JJ et al. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 1995; 23: 1028-1036.
28. Everitt DE, Davis CB, Thompson K et al. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 1996; 174: 463-469.
29. Bleuel H, Hoffmann R, Kaufmann B, Neubert P, Ochlich P, Schaumann W. Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology 1996; 52: 329-338.
30. Halstenson CE, Macres M, Katz AS, et al.Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-712.
31. Martin U, Kohler J, Sponer G, Strein K. Pharma-cokinetics of the Novel recombinant plasmino-gen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 1992; 6: 39-43.
32. Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 2001; 101: 493-500.
33. Oikawa K, Watanabe T, Miyamoto I, Higuchi S. Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 2000; 30: 993-1003.
34. Martin U, Mollendorff EV, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharma-cokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-574.
35. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41: 1229-1245.
36. Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasmonigen activators. Circulation 1991; 84: 1216-1234.
37. Boer DA, Kluft C, Gerloff J et al. Pharmacokinetics of Saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemost 1993; 70: 320-325.
38. Duconge J, Fernandez-Sanchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos 2004; 25: 177-186.
39. Nowak G. Pharmacokinetics of Hirudin. Semin Thromb Hemost 1991; 15: 293-301.
40. Krieter PA, Trapani AJ. Metabolism of atrial natriuretic peptide. Extraction by organs in the rat. Drug Metab Dispos 1989; 17: 14-19.
41. Marleau S, Ong H, De Lean A, du Souich P. Disposition and dynamics of atrial natriuretic factor in conscious rabbits. J Pharmacol Exp Ther 1989; 251: 328-333.
42. Cernacek P, Maher E, Crawhall JC, Levy M. 1988. Renal dose response and pharmacokinetics of atrial natriuretic factor in dogs. Am J Physiol 1988; 255(6 Pt 2): R929-R935.
43. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 1986; 38: 1827-1833.
44. Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lener-cept and their extrapolation to humans. Drug Metab Dispos 1999; 27: 21-25.
45. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299.
46. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos. 2007; 35: 1886-1893.
47. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13: 1551-1559.
48. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49: 1382-1402.
49. Thygesen P, Macheras P, Van Peer A. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 2009; 26: 2543-2550.
50. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24: 1720-1740.